These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

800 related items for PubMed ID: 29636274

  • 1. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
    Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO.
    J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
    [Abstract] [Full Text] [Related]

  • 2. A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE.
    van Dam LS, Osmani Z, Kamerling SWA, Kraaij T, Bakker JA, Scherer HU, Rabelink TJ, Voll RE, Alexander T, Isenberg DA, van Kooten C, Teng YKO.
    Rheumatology (Oxford); 2020 Oct 01; 59(10):2734-2745. PubMed ID: 31951278
    [Abstract] [Full Text] [Related]

  • 3. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
    Kraaij T, Arends EJ, van Dam LS, Kamerling SWA, van Daele PLA, Bredewold OW, Ray A, Bakker JA, Scherer HU, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO.
    Nephrol Dial Transplant; 2021 Jul 23; 36(8):1474-1483. PubMed ID: 32591783
    [Abstract] [Full Text] [Related]

  • 4. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H, Li T, Chen S, Gu Y, Ye S.
    Arthritis Rheumatol; 2015 Dec 23; 67(12):3190-200. PubMed ID: 26245802
    [Abstract] [Full Text] [Related]

  • 5. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR, Gordon C.
    BioDrugs; 2013 Apr 23; 27(2):85-95. PubMed ID: 23456653
    [Abstract] [Full Text] [Related]

  • 6. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R, Anolik JH.
    Drugs; 2006 Apr 23; 66(15):1933-48. PubMed ID: 17100405
    [Abstract] [Full Text] [Related]

  • 7. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
    van Schaik M, Arends EJ, Soonawala D, van Ommen E, de Leeuw K, Limper M, van Paassen P, Huizinga TWJ, Toes REM, van Kooten C, Rotmans JI, Rabelink TJ, Teng YKO.
    Trials; 2022 Nov 12; 23(1):939. PubMed ID: 36371234
    [Abstract] [Full Text] [Related]

  • 9. Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies.
    Petricca L, Gigante MR, Paglionico A, Costanzi S, Vischini G, Di Mario C, Varriano V, Tanti G, Tolusso B, Alivernini S, Grandaliano G, Ferraccioli G, Gremese E.
    Front Med (Lausanne); 2020 Nov 12; 7():553075. PubMed ID: 33195302
    [Abstract] [Full Text] [Related]

  • 10. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, Isenberg DA, Gordon C, Ehrenstein MR.
    BMJ Open; 2019 Dec 16; 9(12):e032569. PubMed ID: 31848169
    [Abstract] [Full Text] [Related]

  • 11. Differential clearance mechanisms, neutrophil extracellular trap degradation and phagocytosis, are operative in systemic lupus erythematosus patients with distinct autoantibody specificities.
    Chauhan SK, Rai R, Singh VV, Rai M, Rai G.
    Immunol Lett; 2015 Dec 16; 168(2):254-9. PubMed ID: 26434792
    [Abstract] [Full Text] [Related]

  • 12. Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series.
    Gualtierotti R, Borghi MO, Gerosa M, Schioppo T, Larghi P, Geginat J, Meroni PL.
    Clin Exp Rheumatol; 2018 Dec 16; 36(4):643-647. PubMed ID: 29533753
    [Abstract] [Full Text] [Related]

  • 13. Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis.
    Bruschi M, Bonanni A, Petretto A, Vaglio A, Pratesi F, Santucci L, Migliorini P, Bertelli R, Galetti M, Belletti S, Cavagna L, Moroni G, Franceschini F, Fredi M, Pazzola G, Allegri L, Sinico RA, Pesce G, Bagnasco M, Manfredi A, Ramirez GA, Ramoino P, Bianchini P, Puppo F, Pupo F, Negrini S, Mattana F, Emmi G, Garibotto G, Santoro D, Scolari F, Ravelli A, Tincani A, Cravedi P, Volpi S, Candiano G, Ghiggeri GM.
    J Rheumatol; 2020 Mar 16; 47(3):377-386. PubMed ID: 31092713
    [Abstract] [Full Text] [Related]

  • 14. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus.
    Sohrabian A, Parodis I, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I, Rönnelid J.
    Arthritis Res Ther; 2019 Nov 29; 21(1):259. PubMed ID: 31783909
    [Abstract] [Full Text] [Related]

  • 15. Intrinsically Distinct Role of Neutrophil Extracellular Trap Formation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Compared to Systemic Lupus Erythematosus.
    van Dam LS, Kraaij T, Kamerling SWA, Bakker JA, Scherer UH, Rabelink TJ, van Kooten C, Teng YKO.
    Arthritis Rheumatol; 2019 Dec 29; 71(12):2047-2058. PubMed ID: 31313503
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
    Muller P, Chowdhury K, Gordon C, Ehrenstein MR, Doré CJ.
    Trials; 2020 Jul 16; 21(1):652. PubMed ID: 32677992
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial.
    Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, Isenberg DA, Doré CJ, Gordon C, Ehrenstein MR, BEAT-LUPUS Investigators.
    Ann Intern Med; 2021 Dec 16; 174(12):1647-1657. PubMed ID: 34698499
    [Abstract] [Full Text] [Related]

  • 18. B-cell-targeted therapy for systemic lupus erythematosus: an update.
    Ding C, Foote S, Jones G.
    BioDrugs; 2008 Dec 16; 22(4):239-49. PubMed ID: 18611066
    [Abstract] [Full Text] [Related]

  • 19. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N, D'Cruz DP.
    Expert Rev Clin Immunol; 2015 Feb 16; 11(2):195-204. PubMed ID: 25543845
    [Abstract] [Full Text] [Related]

  • 20. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
    Poh YJ, Baptista B, D'Cruz DP.
    Expert Rev Clin Immunol; 2017 Oct 16; 13(10):925-938. PubMed ID: 28847197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.